Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for ...

For most of their lives, the two women have stayed tucked away indoors, sidelined by a rare blood disorder that makes the ...

Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s approach to pre-approval inspections.

A new chemical method that could speed up the creation of medicines, materials and products people rely on every day has been developed by University of Hawaiʻi at Mānoa Department of Chemistry ...

A Northwestern team transformed a common chemotherapy drug into a powerful, targeted cancer therapy using spherical nucleic acids. The redesign dramatically boosted drug absorption and cancer-killing ...

Pirates pitcher Paul Skenes is a candidate to bring home another MLB award this month. / Charles LeClaire-Imagn Images With a thrilling 2025 World Series in the books, it’s time to look ahead to MLB ...

Forbes contributors publish independent expert analyses and insights. Gil Press writes about technology, entrepreneurs and innovation. Will AI transform the typical trials and tribulations of drug ...

To date, the U.S. has conducted airstrikes against 14 boats in the Caribbean Sea and Pacific Ocean, killing at least 57 alleged drug smugglers. “We going to kill, you know,” President Trump declared. ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide not only reduce body weight in obesity but are also approved to treat other ...

The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...

Oct 28 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday it was collaborating with Nvidia (NVDA.O), opens new tab to build a supercomputer to help with drug discovery and shorten ...

Something just wasn’t adding up when Dr. Mehmet Oz — the current administrator for the Centers for Medicare and Medicaid service — tried to explain president Trump’s new drug pricing scheme. That ...